echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kelun Pharmaceutical's JAK inhibitor for alopecia areata approved for clinical use

    Kelun Pharmaceutical's JAK inhibitor for alopecia areata approved for clinical use

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 23, the CDE official website showed that Sichuan Kelun Botai’s new class 1 drug KL130008 capsule was approved for clinical use (acceptance number: CXHL2101850/1/2), and clinical trials will be carried out for severe alopecia areata


    Source: CDE official website

    KL130008 Capsule is an innovative small molecule JAK inhibitor independently developed by Kelun Pharmaceutical with intellectual property rights, and is intended for the treatment of rheumatoid arthritis


    According to the Insight database, KL130008 was first approved for clinical use in June 2018 for the treatment of rheumatoid arthritis, and phase II clinical trials have been started


    KL13008 Project Details (Insight)

    From: Insight database project progress module (http://db.


    Kelun Pharmaceutical's innovative drugs mainly come from its subsidiary Kelun Botai


    Columbotai Product Overview

    From: Insight Database Enterprise Analysis Module (http://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.